Hui Zhang

Hui Zhang is an Instructor at the University of Colorado Anschutz Medical Campus within the School of Medicine and Pediatrics-Critical Care Medicine Department. With a dual MD/PhD credential, Zhang focuses on pulmonary hypertension pathophysiology through integrative studies of vascular cell biology, immunology, and metabolic reprogramming.

• Education: MD and PhD degrees, though specific institutions and years not explicitly stated
• Research Themes: Pulmonary hypertension mechanisms, fibroblast-immune cell cross-talk, epigenetic/metabolic regulation, and complement-driven inflammation
• Methodologies: Single-cell transcriptomics, metabolomics, animal models of hypoxia-induced PH

Zhang's recent work examines fibroblast mitochondrial dysfunction via SIRT3 (2024), epigenetic regulation of miRNA-124 in vascular cells (2021), and drug synergy between HDAC inhibitors and sildenafil (2023). These studies reveal a consistent focus on metabolic reprogramming, complement activation, and epigenetic modifiers as therapeutic targets.

Collaborations: Regularly works with Kurt R. Stenmark and Cheng-Jun Hu on pulmonary vascular disease projects. Key contributions appear in Circulation, Am J Respir Cell Mol Biol, and Frontiers in Immunology.